The lipid profile remains an important laboratory assessment to prevent cardiovascular disease. Interpretation of the non-fasting lipid profile has significantly changed based on new information concerning the pathogenesis of atherosclerosis. In particular, the assessment of risk from cholesterol containing particles following triglyceride metabolism (termed remnant cholesterol) can now be done from a lipid profile. In addition, non-HDL cholesterol as calculated from the lipid profile will provide a complete assessment of total circulating cholesterol containing particles. Furthermore, the formula for measurement of LDL cholesterol from a lipid profile has now been revised so that triglyceride levels exert less interference. Finally, the old concept that the “higher the HDL-c, the better” is no longer tenable. New data indicate that the optimal high density lipoprotein level is below 100 mg/dl for both male and female patients. Correct interpretation of the lipid profile will optimize anti-atherosclerotic therapy and reduce the number one cause of death in the United States.
References
[1]
Qin, Z., Yu, L., Zhang, Y., Xu, Q., Li, C., Zhao, S., et al. (2023) Coronary Artery Calcification and Plaque Stability: An Optical Coherence Tomography Study. Heliyon, 9, e23191. https://doi.org/10.1016/j.heliyon.2023.e23191
[2]
Al-Muhaidb, S.M., Aljebreen, A.M.M., AlZamel, Z.A. and Fathala, A. (2020) Prevalence of Noncalcified Plaques and Coronary Artery Stenosis in Patients with Coronary Calcium Scores of Zero. Coronary Artery Disease, 32, 179-183. https://doi.org/10.1097/mca.0000000000000937
[3]
Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2017) Extreme High High-Density Lipoprotein Cholesterol Is Paradoxically Associated with High Mortality in Men and Women: Two Prospective Cohort Studies. European Heart Journal, 38, 2478-2486. https://doi.org/10.1093/eurheartj/ehx163
[4]
Ouimet, M., Barrett, T.J. and Fisher, E.A. (2019) HDL and Reverse Cholesterol Transport. Circulation Research, 124, 1505-1518. https://doi.org/10.1161/circresaha.119.312617
[5]
Riggs, K.A. and Rohatgi, A. (2019) HDL and Reverse Cholesterol Transport Biomarkers. Methodist DeBakey Cardiovascular Journal, 15, 39-46. https://doi.org/10.14797/mdcj-15-1-39
[6]
Martins, J., Steyn, N., Rossouw, H.M. and Pillay, T.S. (2023) Best Practice for LDL-Cholesterol: When and How to Calculate. Journal of Clinical Pathology, 76, 145-152. https://doi.org/10.1136/jcp-2022-208480
[7]
Weaver, O.R., Krysa, J.A., Ye, M., Vena, J.E., Eurich, D.T. and Proctor, S.D. (2023) Nonfasting Remnant Cholesterol and Cardiovascular Disease Risk Prediction in Albertans: A Prospective Cohort Study. CMAJ Open, 11, E645-E653. https://doi.org/10.9778/cmajo.20210318
[8]
Quispe, R., Martin, S.S., Michos, E.D., Lamba, I., Blumenthal, R.S., Saeed, A., et al. (2021) Remnant Cholesterol Predicts Cardiovascular Disease Beyond LDL and ApoB: A Primary Prevention Study. European Heart Journal, 42, 4324-4332. https://doi.org/10.1093/eurheartj/ehab432
[9]
Park, C.S., Yang, H., Han, K., Lee, H., Kang, J., Han, J., et al. (2024) J-Shaped Association between LDL Cholesterol and Cardiovascular Events: A Longitudinal Primary Prevention Cohort of over 2.4 Million People Nationwide. Journal of Advanced Research, 58, 139-147. https://doi.org/10.1016/j.jare.2023.05.003
[10]
Brandt, E.J., Regnier, S.M., Leung, E.K., Chou, S.H., Baron, B.W., Te, H.S., et al. (2015) Management of Lipoprotein X and Its Complications in a Patient with Primary Sclerosing Cholangitis. Clinical Lipidology, 10, 305-312. https://doi.org/10.2217/clp.15.23
[11]
Bhalodkar, N.C., Blum, S. and Enas, E.A. (2006) Accuracy of the Ratio of Triglycerides to High-Density Lipoprotein Cholesterol for Predicting Low-Density Lipoprotein Cholesterol Particle Sizes, Phenotype B, and Particle Concentrations among Asian Indians. The American Journal of Cardiology, 97, 1007-1009. https://doi.org/10.1016/j.amjcard.2005.10.036
[12]
da Luz, P.L., Favarato, D., Faria-Neto, Jr., et al. (2008) High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease. Clinics, 63, 427-432.
[13]
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., et al. (2023) Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk. International Journal of Molecular Sciences, 24, Article 4268. https://doi.org/10.3390/ijms24054268
[14]
Glavinovic, T., Thanassoulis, G., de Graaf, J., Couture, P., Hegele, R.A. and Sniderman, A.D. (2022) Physiological Bases for the Superiority of Apolipoprotein B over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. Journal of the American Heart Association, 11. https://doi.org/10.1161/jaha.122.025858
[15]
Langsted, A. and Nordestgaard, B.G. (2019) Nonfasting versus Fasting Lipid Profile for Cardiovascular Risk Prediction. Pathology, 51, 131-141. https://doi.org/10.1016/j.pathol.2018.09.062
[16]
Grundy, S.M., Stone, N.J., Bailey, A.L, et al. (2019) 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1046-e1081.
